PPD Recognized for Excellence in Clinical Research Training
Brandon Hall Gold Awards honor innovation in employee learning and development
WILMINGTON, N.C.--(BUSINESS WIRE)-- PPD, Inc. (Nasdaq:PPD) has earned recognition for its global employee learning and development program in the Brandon Hall Group Human Capital Management (HCM) Excellence in Learning Awards.
PPD was recognized with the Brandon Hall Gold Award in two categories – “best use of blended learning” for its clinical foundation program, which prepares clinical development employees for success in trial monitoring – and “best advance in learning measurement” for the company’s ability to measure learning effectiveness.
The clinical foundation program, one of PPD’s global employee-training courses, offers instructor-led sessions delivered through virtual customized classrooms, eLearning modules, and hands-on activities and scenarios. It offers an intensive study of clinical trial conduct, based on International Conference on Harmonisation guidelines and U.S. Food and Drug Administration regulations and provides knowledge and practice in skills required to perform clinical trial monitoring tasks.
PPD’s learning measurement model, applied to the company’s full range of employee training modules, is designed to enhance learning while reducing training hours and improving business performance to help fulfill PPD’s objective of fostering industry leading talent and culture.
“Our comprehensive employee learning and development programs empower our employees to perform at their peak, delivering our customers value and quality in their drug development programs,” said Jay Dixon, senior vice president of quality and enterprise learning at PPD. “Our investment in a reliable, consistent and scalable learning measurement program enables our leaders to be informed of the most effective and efficient training initiatives to drive performance. This is a prime example of PPD continually challenging the status quo in its relentless pursuit of excellence.”
Mike Cooke, CEO of the Brandon Hall Group, said, “The Excellence in Learning Awards serve the critical function of reinforcing the essential business benefit of creating great experiences for candidates and employees. All award winners must demonstrate that their HCM programs drive bottom-line business results.”
Award entries were evaluated by a panel of veteran, independent senior industry experts, Brandon Hall Group analysts and executives based upon the following criteria: fitting the need, design of the program, functionality, innovation and overall measurable benefits. Excellence in Learning Awards winners will be honored at the Brandon Hall Group’s HCM Excellence Conference, Jan. 26-28, 2021, at the Hilton West Palm Beach, Florida.
PPD is a leading global contract research organization providing comprehensive, integrated drug development, laboratory and lifecycle management services. Our customers include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 46 countries and more than 24,000 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a firm commitment to quality to help customers bend the cost and time curve of drug development and optimize value in delivering life-changing therapies to improve health. For more information, visit www.ppd.com.
This news release contains forward-looking statements. These statements often include words such as “expect,” “believe,” “project,” “forecast,” “estimate,” “target” and other similar expressions. Although we believe these forward-looking statements are based on reasonable assumptions at the time they are made, you should be aware that many factors could affect our actual financial results, and therefore actual results might differ materially from those expressed in the forward-looking statements. Factors that might materially affect such forward-looking statements include, but are not limited to, the fragmented and highly competitive nature of the drug development services industry; changes in trends in the biopharmaceutical industry; our ability to keep pace with rapid technological changes that could make our services less competitive or obsolete; political, economic and/or regulatory influences and changes; and other factors disclosed under the “Risk Factors” section in our periodic reports filed with the Securities and Exchange Commission (SEC), including our latest Annual Report on Form 10-K and Quarterly Report on Form 10-Q, which is available on our website at https://investors.ppd.com or the SEC’s website at www.sec.gov. We assume no obligation and disclaim any duty to revise or update any forward-looking statements, or make any new forward-looking statement, whether as a result of new information, future events or otherwise, except as required by applicable law.
Source: PPD, Inc.